Inflammatix grabs $102m Series D

Inflammatix, a molecular diagnostics company, has secured $102 million in Series D financing.

Inflammatix, a molecular diagnostics company, has secured $102 million in Series D financing. D1 Capital Partners led the round with participation from other investors that included Northpond Ventures, Khosla Ventures, Think.Health and OSF Healthcare Ventures.

Source: Press Release